Brooks Automation, BioCision Announce Equity Investment and Strategic Collaboration
News Mar 24, 2014
Brooks Automation and BioCision announce they have established a relationship to support the development of technologies to improve temperature control and standardization in the use of biomaterials across multiple industries, including pre-clinical and clinical research and product development. Under the terms of the agreement, Brooks Automation has made a $4 million equity investment in BioCision.
This new collaboration will leverage BioCision’s proven expertise in the development of unique mobile temperature management products and technologies together with Brooks Automation’s advanced research and production capabilities in automated systems for sample storage. The research and product design and engineering teams from both companies will work together to advance development of new, highly adaptable and scalable products to support a range of needs in biomaterial sample handling and biobanking, including products that are fully compatible with existing automated systems and that can serve as stand-alone solutions.
“On a global scale, industries and research centers that use biomaterials have demanded a solution that bridges the gap between outstanding storage capabilities and highly precise and automated systems for sample handling. By uniting the proven capabilities of BioCision and Brooks Automation, this collaboration supports development of a new generation of advanced solutions that will set entirely new performance benchmarks in temperature control and sample standardization,” said Rolf Ehrhardt, MD, PhD, BioCision CEO.
“We are very excited about our investment and joint collaboration with BioCision, which will link our current activities and strategy in the life sciences market segment with their innovative products and technology,” said Dr. Steve Schwartz, CEO of Brooks. “BioCision’s focus on addressing major unmet needs in research and cold chain management has led them to impressive year-over-year revenue growth. Our investment in BioCision launches a relationship with joint product opportunities that have a great potential to be integrated with our existing technology platforms.”
Founded in 2007, BioCision continues to record high double-digit annual sales growth based on rapid market expansion of products in sample handling and biomaterial temperature standardization. The company is the developer of CoolCell® cell freezing devices, which have become the new industry standard for cell cryopreservation in research and clinical applications, including cell therapy.
SLAS Recognizes Paul Hung, Ph.D. of COMBiNATi, Inc. With Innovation Award at SLAS2018News
Hung received the award as recognition of his exceptional podium presentation at the SLAS Annual Conference, Microfluidic Siphoning Array (MSA) – A Novel Scalable Digital PCR Integrated Platform.READ MORE
SLAS2018 New Product Award Showcases Latest in Technological Advancement for Life Sciences Drug Discovery & DevelopmentNews
Three organizations earned a SLAS New Product Award at SLAS2018 in San Diego for their innovative new products that have played an important role in the advancement of life sciences drug discovery and development.READ MORE
SLAS Ignite: Find, Fund and Formalize Research and Technology Partnerships at SLAS2018News
Life sciences professionals and business development dealmakers from all walks of industry, academia and government have a new interchange at SLAS2018 – SLAS Ignite, a series of programs that foster scientific innovation through collaboration, debuts at the 2018 SLAS International Conference and Exhibition.READ MORE
Comments | 0 ADD COMMENT
World Advanced Therapies & Regenerative Medicine Congress
May 16 - May 18, 2018